SCHEMBL941004

SCHEMBL941004

CNCCC(=O)OC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL380895 0.97
SCHEMBL12847481 0.85 TSHR (0.52)
SCHEMBL693895 0.84
SCHEMBL15870724 0.84 TSHR (0.44)
SCHEMBL14028638 0.82
Hydrochloric Acid SCHEMBL380609 0.82 TSHR (0.64)
SCHEMBL694512 0.82 TSHR (0.64)
SCHEMBL10038845 0.82 TSHR (0.50)
SCHEMBL10038847 0.82 TSHR (0.50)
SCHEMBL24310000 0.80 TSHR (0.61)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 327 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116273432-A Beneficiation method for comprehensively recovering rubidium from hard rock type lithium multi-metal ore 广东省科学院资源利用与稀土开发研究所 2023-06-23 CN claimed
CN-102093416-B Method for synthesizing sodium ibandronate Nanjing hengsheng pharmaceutical factory 2013-07-24 CN claimed
US-8420630-B2 Pyrimidine derivatives BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2013-04-16 US claimed
EP-2090571-B1 Pyrimidine derivates, medicaments comprising them, their use and process of their preparation BOEHRINGER INGELHEIM PHARMA (DE) 2012-05-16 EP claimed
US-8178712-B2 Process for the synthesis of Ibandronate sodium CIPLA LTD. (IN) 2012-05-15 US claimed
CN-102093416-A Method for synthesizing sodium ibandronate Nanjing hengsheng pharmaceutical factory 2011-06-15 CN claimed
EP-2038291-B1 PROCESS FOR THE SYNTHESIS OF IBANDRONATE SODIUM CIPLA LTD (IN) 2010-07-14 EP claimed
US-20100152167-A1 PYRIMIDINE DERIVATIVES BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2010-06-17 US claimed
EP-1438053-B1 PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME BOEHRINGER INGELHEIM PHARMA (DE) 2008-09-10 EP claimed
EP-1503994-A1 SUBSTITUTED (THIOXO)CARBONYLAMINO PHENYL URACILES Bayer CropScience AG (DE) 2005-02-09 EP claimed
WO-2003093244-A1 SUBSTITUTED (THIOXO)CARBONYLAMINO PHENYL URACILES BAYER CROPSCIENCE AG (DE) 2003-11-13 WO claimed
US-20030171359-A1 Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-09-11 US claimed
EP-4712961-A2 KRAS G12S AND G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2026-03-25 EP disclosed
EP-4634184-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY Crossfire Oncology Holding B.V. (NL) 2025-10-22 EP disclosed
CN-120025255-A Synthesis method of 3-methylaminopropionic acid 长沙普济生物科技股份有限公司 2025-05-23 CN disclosed
WO-2025072686-A1 KRAS G12D MUTATION TARGETING COMPOUNDS SUMMIT THERAPEUTICS INC. (US) 2025-04-03 WO disclosed
EP-0018549-B1 TETRAHYDROISOQUINOLINE COMPOUNDS, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Tanabe Seiyaku Co., Ltd. (JP) 1981-12-30 EP disclosed
US-4294832-A HYPOTENSIVE AGENTS, ANGIOTENSIN INHIBITORS TANABE SEIYAKU CO., LTD. (JP) 1981-10-13 US disclosed
EP-0018549-A2 Tetrahydroisoquinoline compounds, process for preparing them and pharmaceutical compositions containing them Tanabe Seiyaku Co., Ltd. (JP) 1980-11-12 EP disclosed
US-4012392-A ANALGESICS, MORPHINE ANTAGONISTS ACF CHEMIEFARMA N.V. (NL) 1977-03-15 US disclosed